Posted by Michael Wonder on 06 Mar 2024
Camurus announces FDA acceptance of NDA submission for Oclaiz for treatment of acromegaly
5 March 2024 - PDUFA set to 21 October 2024.
Camurus today announced that the US FDA has accepted for review the company’s new drug application for Oclaiz (CAM2029) for the treatment of patients with acromegaly.
